MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections. Overcoming antiviral...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Summa, Vincenzo, Ludmerer, Steven W., McCauley, John A., Fandozzi, Christine, Burlein, Christine, Claudio, Giuliano, Coleman, Paul J., DiMuzio, Jillian M., Ferrara, Marco, Di Filippo, Marcello, Gates, Adam T., Graham, Donald J., Harper, Steven, Hazuda, Daria J., McHale, Carolyn, Monteagudo, Edith, Pucci, Vincenzo, Rowley, Michael, Rudd, Michael T., Soriano, Aileen, Stahlhut, Mark W., Vacca, Joseph P., Olsen, David B., Liverton, Nigel J., Carroll, Steven S.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2012
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3421554/
https://ncbi.nlm.nih.gov/pubmed/22615282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00324-12
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires